交易中 09-05 10:40:30 美东时间
0.000
0.00%
Disc Medicine reported strong Q2 2025 results, with $650M cash on hand and advancing multiple hematology treatments. Key updates include on-track NDA submission for bitopertin in EPP under accelerated approval, initiation of Phase 2 studies for DISC-3405 in PV, and expected data from DISC-0974 trials in anemia. Recent milestones highlight positive clinical data across programs, supported by a robust financial position.
08-07 12:30
Discipline Fund ETF (BATS:DSCF) declared $0.2491/share quarterly dividend. Payable June 30; for shareholders of record June 27; ex-div June 27. More on Discipline Fund ETF Seeking Alpha’s Quant Rating...
07-01 01:14